ATI-052: Investigational bispecific anti-TSLP/IL4R monoclonal antibody Announced Clearance of ATI-052 Investigational New Drug (IND) Application and Plan to Initiate Phase 1 Trial: Aclaris ...

Detailed price information for Aclaris Therapts (ACRS-Q) from The Globe and Mail including charting and trades.

To develop a diagnostic panel, we used LASSO and SVM algorithms, achieving an accuracy of 84% with the combination of EIF5A, IL4R, and SLC9A8 as key biomarkers, which subsequently were validated in a ...

Fractional exhaled nitric oxide (FeNO) is a marker of IL-13 and elevated baseline levels are associated with an improved response to the anti-IL4R mAb dupilumab. However, FeNO was not measured in the ...

Nuclear receptor subfamily 1 group H member 4 (NR1H4) and Interleukin-4 Receptor (IL4R) emerged as potential biomarkers for OCCC (AUCNR1H4 =0.809; AUCIL4R =0.840). In the validation cohort, AUCNR1H4=0 ...

- Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - “We are entering ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.